<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vasudevan, N.</style></author><author><style face="normal" font="default" size="100%">Routholla, Ganesh</style></author><author><style face="normal" font="default" size="100%">Illa, Giri Teja</style></author><author><style face="normal" font="default" size="100%">Reddy, D. Srinivasa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Synthesis of alpha-ketoamides using potassium superoxide (KO2) as an oxidizing agent</style></title><secondary-title><style face="normal" font="default" size="100%">Tetrahedron</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">alpha-Ketoamide</style></keyword><keyword><style  face="normal" font="default" size="100%">Orexin receptor</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidation</style></keyword><keyword><style  face="normal" font="default" size="100%">Potassium superoxide (KO2)</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUN </style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">76</style></volume><pages><style face="normal" font="default" size="100%">131262</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;A simple and convenient method for the synthesis of alpha-ketoamides by the oxidation of aryl acetamides using potassium superoxide (KO2) as an oxidizing agent is disclosed here. The scope of the developed method is successfully tested with fifteen substrates. In addition, the utility of method has been demonstrated by synthesizing an orexin receptor antagonist, a medicinally interesting compound. (C) 2020 Published by Elsevier Ltd.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">25</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;2.233&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saranya, N. Sathya Sai</style></author><author><style face="normal" font="default" size="100%">Choudhury, Rahul</style></author><author><style face="normal" font="default" size="100%">Routholla, Ganesh</style></author><author><style face="normal" font="default" size="100%">Supekar, Prathmesh R.</style></author><author><style face="normal" font="default" size="100%">R, Nandhakumaar</style></author><author><style face="normal" font="default" size="100%">Martin, Alna Kuriyickal</style></author><author><style face="normal" font="default" size="100%">Muruganandham, Renuga Devi</style></author><author><style face="normal" font="default" size="100%">Kumar, Bokara Kiran</style></author><author><style face="normal" font="default" size="100%">Reddy, D. Srinivasa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ready access to benzodiazocines from tryptamines: a druggable scaffold toward antiviral agents</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Medicinal Chemistry Letters</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Benzodiazocine</style></keyword><keyword><style  face="normal" font="default" size="100%">drug discovery</style></keyword><keyword><style  face="normal" font="default" size="100%">Indole cleavage</style></keyword><keyword><style  face="normal" font="default" size="100%">Lipinski's rule of Five</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2 inhibition</style></keyword><keyword><style  face="normal" font="default" size="100%">Tryptamine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">DEC</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">2362-2367</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	Herein we report the first synthesis of the proposed structure of a benzodiazocine natural product, peganutonin A. Considering the druggable nature of benzodiazocine and its limited exploration in the field of medicinal chemistry, we generalized the approach and created a library of compounds useful for various biological activities. Key steps in present approach include tryptamine cyclization facilitated by tert-butyl hypochlorite and cleavage of the fused indole ring using ozonolysis. Preliminary screening of the synthesized compounds resulted in potent antiviral compounds against the SARS-CoV-2 virus.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	4.0&lt;/p&gt;
</style></custom4></record></records></xml>